Advertisement
Advertisement
SRZN
Surrozen, Inc. Common
28.16
USDSponsored
+0.71
+2.59%
Apr 10, 15:59 UTC -4
Closed
After-Market
28.16
0.00
0.00%
SRZN Earnings Reports
Positive Surprise Ratio
SRZN beat 9 of 17 last estimates.
53%
Next Report
Date of Next Report
May 08, 2026
Estimate for Q1 26 (Revenue/ EPS)
$4.07M
/-$1.24
Implied change from Q4 25 (Revenue/ EPS)
+671.63%
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/-83.31%
Surrozen, Inc. Common earnings per share and revenue
On Mar 23, 2026, SRZN reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -1.21 USD, resulting in a --% surprise. Revenue reached 528.00 thousand, compared to an expected 674.22 thousand, with a -21.69% difference. The market reacted with a +6.12% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -1.24 USD, with revenue projected to reach 4.07 million USD, implying an -- of --% EPS, and increase of 671.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AleAnna, Inc. Class A Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-Actual
$0.00
Surprise
-
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$2.32
Actual
-$2.34
Surprise
-0.62%
FAQ
What were Surrozen, Inc. Common's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Surrozen, Inc. Common reported EPS of --, missing estimates by --, and revenue of $528.00K, -21.69% below expectations.
How did the market react to Surrozen, Inc. Common's Q4 2025 earnings?
The stock price moved up 6.12%, changed from $27.45 before the earnings release to $29.13 the day after.
When is Surrozen, Inc. Common expected to report next?
The next earning report is scheduled for May 08, 2026.
What are the forecasts for Surrozen, Inc. Common's next earnings report?
Based on --
analysts, Surrozen, Inc. Common is expected to report EPS of -$1.24 and revenue of $4.07M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement